Display options
Cite
Carr BI, Guerra V, Giannini EG, et al. A Liver Index and its Relationship to Indices of HCC Aggressiveness. J Integr Oncol. 2016;5(4)doi: 10.4172/2329-6771.1000178.
Carr, B. I., Guerra, V., Giannini, E. G., Farinati, F., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Benvegnù, L., Zoli, M., Borzio, F., Caturelli, E., Masotto, A., & Trevisani, F. (2016). A Liver Index and its Relationship to Indices of HCC Aggressiveness. Journal of integrative oncology, 5(4), . https://doi.org/10.4172/2329-6771.1000178
Carr, Brian I, et al. "A Liver Index and its Relationship to Indices of HCC Aggressiveness." Journal of integrative oncology vol. 5,4 (2016). doi: https://doi.org/10.4172/2329-6771.1000178
Carr BI, Guerra V, Giannini EG, Farinati F, Ciccarese F, Rapaccini GL, Di Marco M, Benvegnù L, Zoli M, Borzio F, Caturelli E, Masotto A, Trevisani F. A Liver Index and its Relationship to Indices of HCC Aggressiveness. J Integr Oncol. 2016 Oct;5(4). doi: 10.4172/2329-6771.1000178. Epub 2016 Sep 05. PMID: 28580457; PMCID: PMC5450974.
Copy Download .nbib Format: NLM
Share it on

J Integr Oncol. 2016 Oct;5(4). doi: 10.4172/2329-6771.1000178. Epub 2016 Sep 05.

A Liver Index and its Relationship to Indices of HCC Aggressiveness.

Journal of integrative oncology

Brian I Carr, Vito Guerra, Edoardo G Giannini, Fabio Farinati, Francesca Ciccarese, Gian Ludovico Rapaccini, Maria Di Marco, Luisa Benvegnù, Marco Zoli, Franco Borzio, Eugenio Caturelli, Alberto Masotto, Franco Trevisani

Affiliations

  1. Izmir Biomedicine and Genome Center, Dokuz Eylul University, Turkey and Lusaka Apex Medical University, Zambia.
  2. Department of Clinical Trials and Epidemiology, IRCCS de Bellis, Castellana Grotte, Italy.
  3. Department of Internal Medicine, Gastroenterology Unit, University of Genoa, Italy.
  4. Department of Surgical Science and Gastroenterology, Gastroenterology Unit, University of Padua, Italy.
  5. Division of Surgery, Policlinico San Marco, Zingonia, Italy.
  6. Internal Medicine and Gastroenterology Unit, Catholic University of Rome, Italy.
  7. Division of Medicine, Azienda Ospedaliera Bolognini, Seriate, Italy.
  8. Department of Clinical and Experimental Medicine, Medical Unit, University of Padua, Italy.
  9. Department of Medical and Surgical Science, Internal Medicine Unit, Alma Mater Studiorum, University of Bologna, Italy.
  10. Department of Medicine, Internal Medicine and Hepatology Unit, Ospedale Fatebenefratelli, Milan, Italy.
  11. Gastroenterology Unit, Ospedale Belcolle, Viterbo, Italy.
  12. Gastroenterology Unit, Ospedale Sacro Cuore Don Calabria, Negrar, Italy.
  13. Department of Medical Surgical Sciences, Medical Semiotics Unit, Alma Mater Studiorum, University of Bologna, Italy.

PMID: 28580457 PMCID: PMC5450974 DOI: 10.4172/2329-6771.1000178

Abstract

A Hepatocellular (HCC) Aggressiveness Index was recently constructed, consisting of the sum of the scores for the 4 clinical parameters of maximum tumor size, multifocality, presence of portal vein thrombus and blood alphafetoprotein levels. It was observed that there was an association with several liver function tests. We have now formed a Liver Index from the 4 liver parameters with the highest hazard ratios with respect to HCC aggressiveness, namely: blood total bilirubin, gamma glutamyl transpeptidase (GGTP), albumin and platelet levels (cirrhosis surrogate). We found that the scores for the Liver Index related significantly to survival, but also to the Aggressiveness Index and to its individual HCC components as well as showing significant trends with the components. These results support the hypothesis that liver function is not only an important prognostic factor in HCC patients, but may also be involved in HCC biology and aggressiveness. Blood albumin, GGTP, albumin and platelet levels were used to create a Liver Index that related significantly to parameters of HCC aggressiveness.

Keywords: Aggressiveness index; HCC; Liver function; Survival

References

  1. Oncology. 2016;90(4):215-20 - PubMed
  2. Cancer. 2006 Nov 1;107(9):2212-22 - PubMed
  3. Semin Oncol. 2014 Jun;41(3):415-21 - PubMed
  4. J Vasc Interv Radiol. 2014 Jul;25(7):1056-66 - PubMed
  5. Jpn J Cancer Res. 1993 Dec;84(12):1237-44 - PubMed
  6. Proc Natl Acad Sci U S A. 2012 Aug 7;109(32):E2165-72 - PubMed
  7. Dig Dis Sci. 2011 Oct;56(10 ):3078-85 - PubMed
  8. World J Gastroenterol. 2014 Aug 21;20(31):10944-52 - PubMed
  9. Oncology. 2012;83(6):339-45 - PubMed
  10. Expert Opin Pharmacother. 2015;16(18):2773-80 - PubMed
  11. Carcinogenesis. 1999 Apr;20(4):553-9 - PubMed
  12. Liver Cancer. 2015 Mar;4(2):126-36 - PubMed
  13. Semin Oncol. 2014 Apr;41(2):252-8 - PubMed
  14. Int J Biol Markers. 2014 Sep 30;29(3):e215-23 - PubMed
  15. J Gastroenterol Hepatol. 2016 Jul;31(7):1300-6 - PubMed
  16. Int J Mol Sci. 2014 Mar 24;15(3):5163-74 - PubMed
  17. Hepatogastroenterology. 2010 Jul-Aug;57(101):869-74 - PubMed
  18. BMC Cancer. 2013 Feb 02;13:52 - PubMed
  19. Eur J Cancer. 2016 Aug;63:25-33 - PubMed
  20. Hepatology. 2005 Jun;41(6):1376-82 - PubMed
  21. Chin Med J (Engl). 2015 Feb 5;128(3):316-21 - PubMed
  22. J Gastroenterol. 2010 Feb;45(2):146-52 - PubMed
  23. Hepatology. 1996 May;23(5):1093-7 - PubMed
  24. Ann Surg Oncol. 2014 Sep;21(9):3084-9 - PubMed
  25. J Gastrointest Dig Syst. 2013 Mar 2;Suppl 12:null - PubMed
  26. BMC Cancer. 2014 Jan 27;14:43 - PubMed
  27. BMC Cancer. 2014 May 21;14:351 - PubMed
  28. Cancer. 1985 Aug 15;56(4):918-28 - PubMed
  29. Carcinogenesis. 1990 Oct;11(10):1857-61 - PubMed
  30. Cancer Cell. 2006 Aug;10(2):99-111 - PubMed

Publication Types

Grant support